Pursuant to article 228 of the restated text of the Securities Market Law, we hereby inform you of the following **SIGNIFICANT EVENT**: 

In compliance with the provision of section 2 of Rule Fourth of Circular 1/2017, of 26 April, of the National Securities Market Commission, on liquidity agreements, the Company announces that on June 4, 2018 has entered into a liquidity agreement (the **Liquidity Agreement**) with JB Capital Markets, Sociedad de Valores, S.A.U. (the **Financial Intermediary**), in order to favor liquidity of transactions and the regularity of trading of their shares.

Pursuant to section 2 a) of said Rule Fourth, the following information is reported:

- Shares of the Liquidity Agreement: PHARMA MAR Shares with ISIN ES0169501030.

- Markets in which operations will take place: The operations will be carried out in the regulated markets, through the open market.

- Contract Term: 12 months, counting from June 5, 2018, being understood tacitly extended for an equal period, unless otherwise indicated by one of the parties.

- Number of shares allocated to the securities account associated with the Liquidity Agreement: 407,319 shares.

- Amount allocated to the cash account associated with the Liquidity Agreement: EUR 600,000